• Je něco špatně v tomto záznamu ?

Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme

D. Vagiannis, Z. Yu, E. Novotna, A. Morell, J. Hofman,

. 2020 ; 178 (-) : 114061. [pub] 20200601

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027955

Entrectinib is a new tyrosine kinase inhibitor that was recently approved for the treatment of ROS1-positive metastatic non-small cell lung cancer (NSCLC). In this study, we aimed to characterize its potential to act as a modulator of pharmacokinetic cytostatic resistance and perpetrator of drug interactions. In accumulation studies, entrectinib exhibited potent inhibition of ABCB1, while only moderate interaction was recorded for ABCG2 and ABCC1 efflux transporters. Furthermore, incubation assays revealed the potential of this drug to inhibit various recombinant cytochrome P450 enzymes, which can be ranked according to inhibitory affinities as follows: CYP2C8 ≈ CYP3A4 > CYP2C9 > CYP2C19 ≈ CYP3A5 > CYP2D6 > CYP2B6 > CYP1A2. Additionally, in silico docking analysis confirmed entrectinib's interactions with ABCB1 and CYP3A4 and resolved their possible molecular background. In subsequent drug combination experiments, we demonstrated the ability of entrectinib to synergize with daunorubicin in various ABCB1-expressing cellular models. Moreover, the comparative proliferation study results suggested that the anticancer efficacy of entrectinib is not affected by the functional presence of tested ABC transporters. In contrast to ABCB1-related data, no resistance reversal effect was recorded for the combination with docetaxel in HepG2-CYP3A4 cells. In the final experimental set, we observed no significant changes in ABCB1, ABCG2, ABCC1 or CYP3A4 gene expression in NSCLC cells exposed to entrectinib. In summary, our work indicates that entrectinib may be a perpetrator of clinically relevant pharmacokinetic drug interactions and modulator of ABCB1-mediated resistance. Our in vitro results might provide a valuable foundation for future clinical investigations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027955
003      
CZ-PrNML
005      
20210114152703.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2020.114061 $2 doi
035    __
$a (PubMed)32497550
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vagiannis, Dimitrios $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
245    10
$a Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme / $c D. Vagiannis, Z. Yu, E. Novotna, A. Morell, J. Hofman,
520    9_
$a Entrectinib is a new tyrosine kinase inhibitor that was recently approved for the treatment of ROS1-positive metastatic non-small cell lung cancer (NSCLC). In this study, we aimed to characterize its potential to act as a modulator of pharmacokinetic cytostatic resistance and perpetrator of drug interactions. In accumulation studies, entrectinib exhibited potent inhibition of ABCB1, while only moderate interaction was recorded for ABCG2 and ABCC1 efflux transporters. Furthermore, incubation assays revealed the potential of this drug to inhibit various recombinant cytochrome P450 enzymes, which can be ranked according to inhibitory affinities as follows: CYP2C8 ≈ CYP3A4 > CYP2C9 > CYP2C19 ≈ CYP3A5 > CYP2D6 > CYP2B6 > CYP1A2. Additionally, in silico docking analysis confirmed entrectinib's interactions with ABCB1 and CYP3A4 and resolved their possible molecular background. In subsequent drug combination experiments, we demonstrated the ability of entrectinib to synergize with daunorubicin in various ABCB1-expressing cellular models. Moreover, the comparative proliferation study results suggested that the anticancer efficacy of entrectinib is not affected by the functional presence of tested ABC transporters. In contrast to ABCB1-related data, no resistance reversal effect was recorded for the combination with docetaxel in HepG2-CYP3A4 cells. In the final experimental set, we observed no significant changes in ABCB1, ABCG2, ABCC1 or CYP3A4 gene expression in NSCLC cells exposed to entrectinib. In summary, our work indicates that entrectinib may be a perpetrator of clinically relevant pharmacokinetic drug interactions and modulator of ABCB1-mediated resistance. Our in vitro results might provide a valuable foundation for future clinical investigations.
650    _2
$a buňky A549 $7 D000072283
650    _2
$a P-glykoproteiny $x antagonisté a inhibitory $x chemie $x metabolismus $7 D018435
650    _2
$a zvířata $7 D000818
650    _2
$a benzamidy $x farmakologie $7 D001549
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a cytochrom P-450 CYP3A $x chemie $x metabolismus $7 D051544
650    _2
$a cytostatické látky $x farmakologie $7 D054697
650    _2
$a psi $7 D004285
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a mnohočetná léková rezistence $x účinky léků $x fyziologie $7 D018432
650    _2
$a chemorezistence $x účinky léků $x fyziologie $7 D019008
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a lidé $7 D006801
650    _2
$a indazoly $x farmakologie $7 D007191
650    _2
$a buňky MDCK $7 D061985
650    _2
$a simulace molekulového dockingu $x metody $7 D062105
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a sekundární struktura proteinů $7 D017433
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Yu, Zhang $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Novotna, Eva $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Morell, Anselm $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Hofman, Jakub $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. Electronic address: jakub.hofman@faf.cuni.cz.
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 178, č. - (2020), s. 114061
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32497550 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152701 $b ABA008
999    __
$a ok $b bmc $g 1608290 $s 1119135
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 178 $c - $d 114061 $e 20200601 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...